Conference Coverage
about 3 hours ago
Q&A: Mark Gillies the outcomes of injecting VEGF inhibitorsLatest News
Advertisement
Shorts
1:56
Most impactful discoveries in 5 decades - Part 6
14 days ago
by
Martin David Harp
1:28
Most impactful discoveries in 5 decades - Part 5
14 days ago
by
Martin David Harp
1:34
Most impactful discoveries in 5 decades - Part 4
14 days ago
by
Martin David Harp
1:51
Most impactful discoveries in 5 decades - Part 3
14 days ago
by
Martin David Harp
1:41
Most impactful discoveries in 5 decades - Part 2
14 days ago
by
Martin David Harp
1:18
Most impactful discoveries in 5 decades
14 days ago
by
Martin David Harp
Ophthalmology Times Digital Edition
Virtual reality and artificial intelligence are reshaping medical education.
Alfredo Sadun, MD, PhD, details an unexpected outcome from a gene therapy in development for Leber hereditary optic neuropathy (LHON).
Recapping the Heidelberg Engineering International SPECTRALIS Symposium—and Beyond.
Surgical tools improve Schlemm canal access and enable earlier glaucoma care.
A novel use of minor salivary glands offers lasting relief and visual improvement.
Innovation, adaptability, and clear communication are key to managing outcomes.
Surgeons navigate unpredictable healing and anatomy with customized strategies.
Understand the anatomical risks, technique-specific benefits, and patient selection criteria
Advances address a need for the growing populace with age-related near vision loss.
Fovea-sparing, multifocal, and bilateral lesions exhibited the fastest growth rates.
Podcasts
Continuing Medical Education
Advertisement
All News
Advertisement
Smith highlights advances in interventional glaucoma, including first-line SLT, emerging surgical options, and co-management strategies, during the Ophthalmology Times and Optometry Times EyeCon 2025 conference.
This new technology, the MacuMira system, is a non-invasive treatment now available in more than 150 clinics across Canada.
Residents across ophthalmology, optometry, and retina care were recognized for leadership, research, and dedication to advancing patient care.
Broadwood Partners, who is against the merger, holds approximately 27.5% of the outstanding common stock of STAAR, making them the largest outside stockholder of STAAR.
Considering rapid increases in myopia, authors conducted a longitudinal cohort study of twins and their parents with the goal of exploring the intergenerational changes in the myopia epidemic in China.
A study reveals that repetitive head impacts in college football players do not significantly affect smooth pursuit eye movement velocity during a season.
In honor of looking back at 50 years, we look forward at a world where the toughest eye diseases could be cured in the blink of an eye.
Research on methotrexate's role in PVR retinal detachment surgery shows promising visual improvements, potentially transforming treatment strategies in ophthalmology.
Advertisement
Canadian researchers reveal increased complications in cataract surgeries during the COVID-19 pandemic, highlighting risks and factors affecting outcomes.
Bimatoprost ophthalmic solution 0.01% is a prostaglandin analog for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension and is the generic equivalent of LUMIGAN.
EYLUXVI (ALT-L9) is an aflibercept (Eylea) biosimilar from Alteogen, co-developed by its subsidiary, Alteogen Biologics.
The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.
Advertisement
Advertisement
.png "Optometry Times"){kind=logo}
